| Literature DB >> 32017919 |
Shihua Yao1, Tuong-Vi Nguyen1, Alan Rolfe1, Anant A Agrawal1, Jiyuan Ke1, Shouyong Peng1, Federico Colombo1, Sean Yu2, Patricia Bouchard3, Jiayi Wu1, Kuan-Chun Huang1, Xingfeng Bao1, Kiyoyuki Omoto1, Anand Selvaraj1, Lihua Yu1, Stephanos Ioannidis1, Frédéric H Vaillancourt1, Ping Zhu1, Nicholas A Larsen1, David M Bolduc4.
Abstract
Carbamoyl phosphate synthetase 1 (CPS1) catalyzes the first step in the ammonia-detoxifying urea cycle, converting ammonia to carbamoyl phosphate under physiologic conditions. In cancer, CPS1 overexpression supports pyrimidine synthesis to promote tumor growth in some cancer types, while in others CPS1 activity prevents the buildup of toxic levels of intratumoral ammonia to allow for sustained tumor growth. Targeted CPS1 inhibitors may, therefore, provide a therapeutic benefit for cancer patients with tumors overexpressing CPS1. Herein, we describe the discovery of small-molecule CPS1 inhibitors that bind to a previously unknown allosteric pocket to block ATP hydrolysis in the first step of carbamoyl phosphate synthesis. CPS1 inhibitors are active in cellular assays, blocking both urea synthesis and CPS1 support of the pyrimidine biosynthetic pathway, while having no activity against CPS2. These newly discovered CPS1 inhibitors are a first step toward providing researchers with valuable tools for probing CPS1 cancer biology.Entities:
Keywords: CPS1; carbamoyl phosphate synthetase 1; chemical probe; high-throughput screen; inhibitor; pyrimidine synthesis; urea cycle
Mesh:
Substances:
Year: 2020 PMID: 32017919 DOI: 10.1016/j.chembiol.2020.01.009
Source DB: PubMed Journal: Cell Chem Biol ISSN: 2451-9448 Impact factor: 8.116